ARCHIVES

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

This article is from The Cancer Letter archive.

Vol. 25 No. 15 | April 16, 1999

Download PDF Visit The Full Archive

Related Articles

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

November 16, 2012

Waxman To Speak At AACI Meeting

January 12, 1979

LeMaistre Blasts “Death Merchants’ In tobacco Industry

May 5, 1989

Reinventing NCI: Prevention Program Lacks Leadership, Reorganization Needed, Advisory Group Says

June 20, 1997

Scientists Falsified Research, ORI Says

July 5, 1996

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

May 2, 2008